Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of $59.00. Mani Foroohar has given his Sell rating
Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of $59.00. Mani Foroohar has given his Sell rating
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Moderna (MRNA – Research Report), Altimmune (ALT – Research Report) and Bausch Health Companies (BHC – Research Report) with bullish sentiments.
Moderna (MRNA)
Jefferies analyst Michael Yee maintained a Buy rating on Moderna today and set a price target of $125.00. The company’s shares closed last Wednesday at $110.59.
According to TipRanks.com, Yee is a 3-star analyst with an average return of
Currently, the analyst consensus on Moderna is a Moderate Buy with an average price target of $134.69, implying a 22.9% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $206.00 price target.
See the top stocks recommended by analysts >>
Altimmune (ALT)
Jefferies analyst Roger Song maintained a Buy rating on Altimmune today and set a price target of $35.00. The company’s shares closed last Wednesday at $8.89.
According to TipRanks.com, Song has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $24.00, implying a 157.5% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $25.00 price target.
Bausch Health Companies (BHC)
Jefferies analyst Glen Santangelo maintained a Buy rating on Bausch Health Companies today and set a price target of $16.00. The company’s shares closed last Wednesday at $10.49, equals to its 52-week high of $10.49.
According to TipRanks.com, Santangelo is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Bausch Health Companies with a $10.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRNA:
Goldman Sachs analyst Salveen Richter has maintained their bullish stance on MRNA stock, giving a Buy rating today. Salveen Richter has given his Buy rating due to a combination of
William Maughan, an analyst from Canaccord Genuity, maintained the Hold rating on Moderna (MRNA – Research Report). The associated price target remains the same with $91.00. William Maughan has given
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Integer Holdings (ITGR – Research Report), Akebia Therapeutics (AKBA – Research Report) and Moderna (MRNA – Research Report) with bullish sentiments.
Integer Holdings (ITGR)
In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Integer Holdings, with a price target of $130.00. The company’s shares closed last Wednesday at $115.06, close to its 52-week high of $118.15.
According to TipRanks.com, Wasserman is a 1-star analyst with an average return of
Currently, the analyst consensus on Integer Holdings is a Strong Buy with an average price target of $121.00, a 7.5% upside from current levels. In a report issued on March 14, C.L. King also initiated coverage with a Buy rating on the stock with a $137.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Akebia Therapeutics (AKBA)
In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Akebia Therapeutics, with a price target of $4.00. The company’s shares closed last Wednesday at $2.24, close to its 52-week high of $2.34.
According to TipRanks.com, Bratzel is a 4-star analyst with an average return of
Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.33, implying an 110.2% upside from current levels. In a report issued on March 15, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.
Moderna (MRNA)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Moderna, with a price target of $214.00. The company’s shares closed last Wednesday at $110.59.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
Moderna has an analyst consensus of Moderate Buy, with a price target consensus of $129.27, implying a 18.0% upside from current levels. In a report released yesterday, UBS also reiterated a Buy rating on the stock with a $143.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ITGR: